Aclaris Therapeutics (ACRS) Short Interest Ratio & Short Volume → Now Open: Crypto emergency update (From InvestorPlace) (Ad) Free ACRS Stock Alerts $1.23 0.00 (0.00%) (As of 04/18/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Aclaris Therapeutics Short Interest DataCurrent Short Volume4,890,000 sharesPrevious Short Volume5,120,000 sharesChange Vs. Previous Month-4.49%Dollar Volume Sold Short$6.06 millionShort Interest Ratio / Days to Cover3.0Last Record DateMarch 31, 2024Outstanding Shares70,930,000 sharesPercentage of Shares Shorted6.89%Today's Trading Volume645,828 sharesAverage Trading Volume1,546,490 sharesToday's Volume Vs. Average42% Short Selling Aclaris Therapeutics ? Sign up to receive the latest short interest report for Aclaris Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatACRS Short Interest Over TimeACRS Days to Cover Over TimeACRS Percentage of Float Shorted Over Time Ad InvestorPlaceNow Open: Crypto emergency updateDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. Aclaris Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20244,890,000 shares $6.06 million -4.5%N/A3 $1.24 3/15/20245,120,000 shares $5.99 million -16.1%N/A2.9 $1.17 2/29/20246,100,000 shares $7.26 million +4.6%N/A2.8 $1.19 2/15/20245,830,000 shares $7.17 million -7.9%N/A2.4 $1.23 1/31/20246,330,000 shares $7.34 million -0.5%N/A1.3 $1.16 1/15/20246,360,000 shares $5.88 million +9.8%N/A1.3 $0.92 Get the Latest News and Ratings for ACRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20235,790,000 shares $6.08 million -2.0%N/A1.3 $1.05 12/15/20235,910,000 shares $5.97 million +24.2%N/A1.4 $1.01 11/30/20234,760,000 shares $4.16 million -35.6%N/A1.1 $0.87 11/15/20237,390,000 shares $5.92 million +12.3%N/A2 $0.80 10/31/20236,580,000 shares $32.77 million +8.8%N/A6.5 $4.98 10/15/20236,050,000 shares $32.19 million +2.0%N/A7.2 $5.32 9/30/20235,930,000 shares $40.62 million -9.1%N/A7.8 $6.85 9/15/20236,520,000 shares $49.23 million +14.4%N/A9.1 $7.55 8/31/20235,700,000 shares $42.64 million +10.5%N/A8.3 $7.48 8/15/20235,160,000 shares $40.09 million -1.0%N/A8.4 $7.77 7/31/20235,210,000 shares $51.42 million +4.2%N/A8.7 $9.87 7/15/20235,000,000 shares $54.75 million -5.3%N/A7.9 $10.95 6/30/20235,280,000 shares $54.75 million +14.0%N/A8.2 $10.37 6/15/20234,630,000 shares $45.88 million -2.7%N/A6.5 $9.91 5/31/20234,760,000 shares $39.75 million +2.4%N/A6.8 $8.35 5/15/20234,650,000 shares $38.69 million -5.3%N/A4.5 $8.32 4/30/20234,910,000 shares $43.65 million -1.4%9.8%4.4 $8.89 4/15/20234,980,000 shares $44.02 million +3.8%9.9%4.4 $8.84 3/31/20234,800,000 shares $38.83 million +14.8%9.5%4.4 $8.09 3/15/20234,180,000 shares $33.40 million +26.7%8.1%4.2 $7.99 2/28/20233,300,000 shares $41.12 million +8.9%6.4%3.7 $12.46 2/15/20233,030,000 shares $39.66 million +14.3%5.9%5.4 $13.09 1/31/20232,650,000 shares $44.79 million -6.7%5.2%5.8 $16.90 1/15/20232,840,000 shares $50.98 million -5.0%5.5%8.1 $17.95 12/30/20222,990,000 shares $47.09 million +12.4%5.8%9 $15.75 12/15/20222,660,000 shares $41.63 million -4.0%5.2%7.9 $15.65 11/30/20222,770,000 shares $42.16 million -14.0%5.4%7.8 $15.22 11/15/20223,220,000 shares $57.90 million -12.5%6.3%9.4 $17.98 10/31/20223,680,000 shares $57.44 million -4.9%7.1%10.9 $15.61 10/15/20223,870,000 shares $60.84 million +7.2%7.5%11.4 $15.72 9/30/20223,610,000 shares $56.82 million +9.4%7.0%11.3 $15.74 9/15/20223,300,000 shares $47.49 million +5.1%6.4%9.5 $14.39 8/31/20223,140,000 shares $49.96 million -10.0%6.1%8.9 $15.91 8/15/20223,490,000 shares $58.49 million -1.4%6.8%9.8 $16.76You’re invited: Biggest crypto event of 2024 (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. ACRS Short Interest - Frequently Asked Questions What is Aclaris Therapeutics' current short interest? Short interest is the volume of Aclaris Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 4,890,000 shares of ACRS short. Learn More on Aclaris Therapeutics' current short interest. What is a good short interest ratio for Aclaris Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ACRS shares currently have a short interest ratio of 3.0. Learn More on Aclaris Therapeutics's short interest ratio. Which institutional investors are shorting Aclaris Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Aclaris Therapeutics: Perceptive Advisors LLC, Citadel Advisors LLC, Affinity Asset Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Aclaris Therapeutics' short interest increasing or decreasing? Aclaris Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 4,890,000 shares, a decline of 4.5% from the previous total of 5,120,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Aclaris Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Aclaris Therapeutics: Clearside Biomedical, Inc. (0.30%), DiaMedica Therapeutics Inc. (0.53%), PMV Pharmaceuticals, Inc. (6.40%), Chimerix, Inc. (1.56%), BioXcel Therapeutics, Inc. (10.54%), Eton Pharmaceuticals, Inc. (0.98%), Oncolytics Biotech Inc. (1.23%), Affimed (1.51%), Allakos Inc. (6.33%), Hookipa Pharma Inc (0.45%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Aclaris Therapeutics stock? Short selling ACRS is an investing strategy that aims to generate trading profit from Aclaris Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aclaris Therapeutics? A short squeeze for Aclaris Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ACRS, which in turn drives the price of the stock up even further. How often is Aclaris Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ACRS, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: CLSD Short Interest DMAC Short Interest PMVP Short Interest CMRX Short Interest BTAI Short Interest ETON Short Interest ONCY Short Interest AFMD Short Interest ALLK Short Interest HOOK Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ACRS) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle Publishing